Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Diagnostic and therapeutic approaches to multiple myeloma patients: 'Real-world' data from representative multicentre treatment surveys in Germany between 2008 and 2011.

Moehler TM, Merz M, Kellermann L, Goldschmidt H, Knauf W.

Oncol Lett. 2016 Dec;12(6):5043-5051. doi: 10.3892/ol.2016.5375. Epub 2016 Nov 10.

2.

Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma.

Hillengass J, Ritsch J, Merz M, Wagner B, Kunz C, Hielscher T, Laue H, Bäuerle T, Zechmann CM, Ho AD, Schlemmer HP, Goldschmidt H, Moehler TM, Delorme S.

Br J Haematol. 2016 Jul;174(1):127-35. doi: 10.1111/bjh.14038. Epub 2016 Mar 15.

PMID:
26991959
3.

Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.

Merz M, Moehler TM, Ritsch J, Bäuerle T, Zechmann CM, Wagner B, Jauch A, Hose D, Kunz C, Hielscher T, Laue H, Goldschmidt H, Delorme S, Hillengass J.

Eur Radiol. 2016 May;26(5):1404-11. doi: 10.1007/s00330-015-3928-4. Epub 2015 Jul 29.

PMID:
26215436
4.

The application of Gadopentate-Dimeneglumin has no impact on progression free and overall survival as well as renal function in patients with monoclonal plasma cell disorders if general precautions are taken.

Hillengass J, Stoll J, Zechmann CM, Kunz C, Wagner B, Heiss C, Sumkauskaite M, Moehler TM, Schlemmer HP, Goldschmidt H, Delorme S.

Eur Radiol. 2015 Mar;25(3):745-50. doi: 10.1007/s00330-014-3458-5. Epub 2014 Oct 31.

PMID:
25358594
5.

The glycome of normal and malignant plasma cells.

Moehler TM, Seckinger A, Hose D, Andrulis M, Moreaux J, Hielscher T, Willhauck-Fleckenstein M, Merling A, Bertsch U, Jauch A, Goldschmidt H, Klein B, Schwartz-Albiez R.

PLoS One. 2013 Dec 26;8(12):e83719. doi: 10.1371/journal.pone.0083719. eCollection 2013.

6.

Treatment with Thalidomide and Cyclophosphamide (TCID) is Superior to Vincristine (VID) and to Vinorelbine (VRID) Regimens in Patients with Refractory or Recurrent Multiple Myeloma.

Auel B, Goldschmidt H, Geer T, Moehler TM, Platzbecker U, Naumann R, Blau I, Hänel M, Knauf W, Nückel H, Salwender HJ, Scheid C, Weisel K, Gorschlüter M, Glasmacher A, Schmidt-Wolf IG; German Refractory Myeloma Study Group.

Indian J Hematol Blood Transfus. 2012 Jun;28(2):67-76. doi: 10.1007/s12288-011-0103-1. Epub 2011 Aug 18.

7.

Bisphosphonate treatment and renal function in 201 myeloma patients undergoing stem cell transplantation.

Schmitt S, Hielscher T, Baldus C, Neben K, Egerer G, Hillengaß J, Raab M, Hose D, Ho AD, Bergner R, Goldschmidt H, Moehler TM.

Int J Hematol. 2013 Jun;97(6):765-72. doi: 10.1007/s12185-013-1320-1. Epub 2013 Apr 25.

PMID:
23616219
8.

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Kropff M, Baylon HG, Hillengass J, Robak T, Hajek R, Liebisch P, Goranov S, Hulin C, Bladé J, Caravita T, Avet-Loiseau H, Moehler TM, Pattou C, Lucy L, Kueenburg E, Glasmacher A, Zerbib R, Facon T.

Haematologica. 2012 May;97(5):784-91. doi: 10.3324/haematol.2011.044271. Epub 2011 Dec 1.

9.

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.

Moehler TM, Feneberg R, Ho AD, Golenkov AK, Ludwig H, Kropff M, Khuageva NK, Hajda J, von Broen I, Goldschmidt H.

Anticancer Drugs. 2010 Aug;21(7):708-15. doi: 10.1097/CAD.0b013e32833b975b.

PMID:
20571355
10.

Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.

Hillengass J, Fechtner K, Weber MA, Bäuerle T, Ayyaz S, Heiss C, Hielscher T, Moehler TM, Egerer G, Neben K, Ho AD, Kauczor HU, Delorme S, Goldschmidt H.

J Clin Oncol. 2010 Mar 20;28(9):1606-10. doi: 10.1200/JCO.2009.25.5356. Epub 2010 Feb 22.

PMID:
20177023
11.

Transcriptional regulation of the vascular endothelial glycome by angiogenic and inflammatory signalling.

Willhauck-Fleckenstein M, Moehler TM, Merling A, Pusunc S, Goldschmidt H, Schwartz-Albiez R.

Angiogenesis. 2010 Mar;13(1):25-42. doi: 10.1007/s10456-010-9162-4. Epub 2010 Feb 17.

PMID:
20162350
12.

Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging.

Bäuerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM, Christiane H, Wagner-Gund B, Neben K, Kauczor HU, Goldschmidt H, Delorme S.

Radiology. 2009 Aug;252(2):477-85. doi: 10.1148/radiol.2522081756.

PMID:
19703885
13.

Clinical evidence for immunomodulation induced by high-dose melphalan and autologous blood stem cell transplantation as cause for complete clinical remission of multiple myeloma-associated cryoglobulin-vasculitis.

Hillengass J, Ho AD, Goldschmidt H, Waldherr R, Moehler TM.

Int J Hematol. 2008 Nov;88(4):454-456. doi: 10.1007/s12185-008-0177-1. Epub 2008 Oct 11.

PMID:
18846323
14.

Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma.

Hillengass J, Zechmann CM, Nadler A, Hose D, Cremer FW, Jauch A, Heiss C, Benner A, Ho AD, Bartram CR, Kauczor HU, Delorme S, Goldschmidt H, Moehler TM.

Int J Cancer. 2008 Jun 15;122(12):2871-5. doi: 10.1002/ijc.23455.

15.

Successful autologous peripheral blood stem cell transplantation in a Jehovah's Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products.

Schmitt S, Mailaender V, Egerer G, Leo A, Becker S, Reinhardt P, Wiesneth M, Schrezenmeier H, Ho AD, Goldschmidt H, Moehler TM.

Int J Hematol. 2008 Apr;87(3):289-97. doi: 10.1007/s12185-008-0055-x. Epub 2008 Mar 4. Review.

PMID:
18317881
16.

Involvement of alpha 1-2-fucosyltransferase I (FUT1) and surface-expressed Lewis(y) (CD174) in first endothelial cell-cell contacts during angiogenesis.

Moehler TM, Sauer S, Witzel M, Andrulis M, Garcia-Vallejo JJ, Grobholz R, Willhauck-Fleckenstein M, Greiner A, Goldschmidt H, Schwartz-Albiez R.

J Cell Physiol. 2008 Apr;215(1):27-36. doi: 10.1002/jcp.21285.

PMID:
18205178
17.

Lumbar bone marrow microcirculation measurements from dynamic contrast-enhanced magnetic resonance imaging is a predictor of event-free survival in progressive multiple myeloma.

Hillengass J, Wasser K, Delorme S, Kiessling F, Zechmann C, Benner A, Kauczor HU, Ho AD, Goldschmidt H, Moehler TM.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):475-81.

18.

Thalidomide in multiple myeloma.

Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H.

Curr Pharm Biotechnol. 2006 Dec;7(6):431-40. Review.

PMID:
17168659
19.

Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma.

Schlenzka J, Moehler TM, Kipriyanov SM, Kornacker M, Benner A, Bähre A, Stassar MJ, Schäfer HJ, Little M, Goldschmidt H, Cochlovius B.

Anticancer Drugs. 2004 Oct;15(9):915-9.

PMID:
15457133
20.

Antiangiogenic therapy in hematologic malignancies.

Moehler TM, Hillengass J, Goldschmidt H, Ho AD.

Curr Pharm Des. 2004;10(11):1221-34. Review.

PMID:
15078137
21.

Angiogenesis in hematologic malignancies.

Moehler TM, Ho AD, Goldschmidt H, Barlogie B.

Crit Rev Oncol Hematol. 2003 Mar;45(3):227-44. Review.

PMID:
12633837
22.

Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma.

Neben K, Mytilineos J, Moehler TM, Preiss A, Kraemer A, Ho AD, Opelz G, Goldschmidt H.

Blood. 2002 Sep 15;100(6):2263-5.

PMID:
12200397
23.

Angiogenesis in hematologic malignancies.

Moehler TM, Neben K, Ho AD, Goldschmidt H.

Ann Hematol. 2001 Dec;80(12):695-705. Epub 2001 Nov 14. Review.

PMID:
11797109
24.

Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.

Moehler TM, Neben K, Benner A, Egerer G, Krasniqi F, Ho AD, Goldschmidt H.

Blood. 2001 Dec 15;98(13):3846-8.

PMID:
11739195
25.

Bone marrow microcirculation analysis in multiple myeloma by contrast-enhanced dynamic magnetic resonance imaging.

Moehler TM, Hawighorst H, Neben K, Egerer G, Hillengass J, Max R, Benner A, Ho AD, van Kaick G, Goldschmidt H.

Int J Cancer. 2001 Sep;93(6):862-8.

26.

[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma].

Moehler TM, Hawighorst H, Neben K, Egerer G, Benner A, Hillengass J, Max R, Ho AD, Goldschmidt H, van Kaick G.

Radiologe. 2000 Aug;40(8):723-30. German.

PMID:
11006943

Supplemental Content

Loading ...
Support Center